MYC and diffuse large B-cell lymphoma: However, monotherapy in patients with r/r DLBCL and HGBL in the presence of MYC alterations achieved an extended duration of reflection, and combination therapies or biomarker-based patient selection strategies may lead to higher response rates in future clinical trials.